Plasma cell leukemia 3 months after autologous blood cell transplantation for multiple myeloma.
We describe a patient with multiple myeloma who was treated with intensive therapy and autologous blood cell transplantation as her first-line treatment. The disease relapsed 3 months after the transplant as plasma cell leukemia and the patient succumbed in 4 weeks. We suggest that an aggressive plasma cell clone may be selected during the course of intensive treatment. Complex karyotypic findings are also presented.
Koskela
K
K
Department of Medicine, Turku University Central Hospital, MediCity Research Center, Finland.
Pelliniemi
T T
TT
Lakkala
T
T
Remes
K
K
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007621:Karyotyping; D007952:Leukemia, Plasma Cell / Q000209:etiology* / Q000235:genetics; D009101:Multiple Myeloma / Q000150:complications / Q000235:genetics / Q000628:therapy*; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin